COVID-19 Patient Mortality with Convalescent Plasma Therapy: Meta-Analysis

Fathiyyatu Assa’diy Firda¹, Bhisma Murti¹, Cri Sajjana Prajna Wekadigunawan²

¹Masters Program in Public Health, Universitas Sebelas Maret
²Universitas Esa Unggul, Jakarta, Indonesia

ABSTRACT

Background: The use of convalescent plasma was recommended as empiric treatment during the Ebola virus outbreak in 2014, and a protocol for the treatment of Middle East Respiratory Syndrome coronavirus (MERS) with convalescent plasma was created in 2015. These findings raise the hypothesis that the use of convalescent plasma transfusion may be beneficial in SARS-infected patients. The aim of this study was to estimate the mortality risk of COVID-19 patients with convalescent plasma therapy.

Subjects and method: A systematic review and meta-analysis was carried out by collecting articles from the Google Scholar, PubMed, and Science Direct databases. The articles were screened using the PICO model, including: (1) Population = confirmed COVID-19 patients, (2) Intervention = convalescent plasma therapy, (3) Comparison = standard of care, and (4) Outcome = mortality. The keywords used were “Convalescent plasma therapy” OR “Convalescent plasma transfusion” AND “Mortality” OR “death” AND “COVID-19” OR “Coronavirus disease 2019” OR “SARS-Cov-2’. Inclusion criteria were full text, randomized control trials, published from 2020 to 2021, and reported risk ratios. Articles were collected using PRISMA diagrams and quantitative syntheses were assessed using Review Manager (RevMan 5.3).

Results: The meta-analysis was conducted using 9 randomized controlled trial articles involving 4,540 confirmed COVID-19 patients from India, Bahrain, Chile, Netherlands, United States, China, Argentina, New York, and Brazil. This study showed that convalescent plasma therapy reduced mortality in confirmed COVID-19 patients, and was statistically significant (RR = 0.77; 95% CI = 0.64 to 0.93; p = 0.008). The heterogeneity of the study data showed I² = 3%, we found significant inter-study heterogeneity and estimates were made using the fixed effect model.

Conclusion: Convalescent plasma therapy reduces mortality in confirmed COVID-19 patients, and is statistically significant.

Keywords: COVID-19, convalescent plasma therapy, mortality

Correspondence:

Cite this as:

BACKGROUND

Infection with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new single-stranded RNA (ribonucleic acid) virus variant belonging to the coronavirus family, has received global attention, and the World Health Organization (WHO) declared the disease corona virus disease 2019 (COVID-19) as a Public Health Emergency of International Concern on 30 January
2020, and a pandemic on 11 March 2020. Between 31 December 2019 and 29 July 2020, more than 16 million cases of COVID-19 were reported worldwide, accounting for more than 660,000 death. Most COVID-19 patients have mild disease and recover without any treatment. However, older individuals with comorbidities such as diabetes mellitus, hypertension, and respiratory or cardiovascular disease have a greater risk of complications and death (Choi, 2020).

Several treatments have been shown to be effective for COVID-19. Administration of convalescent plasma, which is widely used in viral infections that induce neutralizing antibodies. It is used during outbreaks of severe acute respiratory illness caused by other coronaviruses, SARS-CoV-1 and MERS-CoV, with varying results and when given early, it reduces the length of hospital stay. The use of convalescent plasma has an acceptable safety profile and its administration is a viable approach to adopt during a pandemic. In COVID-19, it may reduce the viral load, improve clinical status, and decrease mortality. On March 24, 2020, the Food and Drug Administration of the United States (FDA) launched an expanded Access Program to collect convalescent plasma donated by individuals who have recovered from COVID-19, and on August 23, 2020 approved emergency use. A study conducted on 20,000 patients confirmed the safety of convalescent plasma. Whereas in a study of 30,000 patients, the same group of investigators showed a reduction in mortality when convalescent plasma was administered early in the course of COVID-19. Convalescent plasma is currently being evaluated in 126 clinical trials (M. Salazar et al., 2021).

Meta-analysis is an epidemiological design that aims to systematically examine and combine quantitative estimation results from a number of previous studies that answer the same research problem and can be combined (Mikolajewicz & Komarova, 2019). Many primary studies have investigated the effect of convalescent plasma therapy on reducing mortality in COVID-19 patients. Further analysis is needed to arrive at a convincing conclusion.

The aim of this study was to estimate the risk of death of COVID-19 patients with convalescent plasma therapy.

### SUBJECTS AND METHOD

#### 1. Study Design

The design of this study is a systematic review and meta-analysis that uses secondary data from previous research results from the Google Scholar, PubMed, and Science Direct databases with the range of 2020-2021. The search keywords for the article were as follows: “Convalescent plasma therapy” OR “Convalescent plasma transfusion” AND “Mortality” OR “death” AND “COVID-19” OR “Coronavirus disease 2019” OR “SARS-Cov-2”.

#### 2. Inclusion Criteria

The inclusion criteria in this study were full paper articles using an RCT (Randomized Control Trial) study design, the relationship measure used was the Risk Ratio, the study subjects were patients with confirmed COVID-19, the intervention provided was convalescent plasma therapy, and the outcome of the study was mortality (death).

#### 3. Exclusion Criteria

Articles published in languages other than English, duplicated articles, Observational studies, articles before 2020

#### 4. Operational Definition of Variable

Convalescent plasma therapy is the administration of blood plasma from patients who have recovered from COVID-19 with certain criteria given as passive immunity in patients with COVID-19.
5. Data Analysis
Data processing in this study was carried out by identifying articles obtained from several databases, followed by screening to obtain articles that met the requirements. Then the quality of the study was assessed using the Critical Appraisal of a Randomized Control Study from the Center for Evidence Based Management (CEBM). The articles that passed this stage were analyzed using RevMan 5.3 Software.

RESULTS
The initial search process in the database yielded 1472 articles and there were additional 38 articles identified from other searches, then through the process of deleting duplicate articles as many as 458 articles with 1052 articles filtered of which qualified for further full text review. The results of the articles that met the qualitative requirements were reviewed again and there were 9 articles that met the quantitative requirements (Figure 1).

Figure 1. PRISMA flow diagram
The forest plot can be seen in Figure 2, the results of the meta-analysis in the study of convalescent plasma therapy reduced the risk of death in COVID-19 patients and were statistically significant (RR= 0.77; 95% CI= 0.64 to 0.93; p= 0.008). The heterogeneity of the research data shows $I^2= 3\%$. The heterogeneity ($I^2$) of this meta-analysis was less than 50% so we calculated the relative risk (RR) using the fixed effect model (Akobeng, 2005 in Murti, 2018).
Table 1. Description of the primary studies in the meta-analysis

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Title</th>
<th>Country</th>
<th>Study Design</th>
<th>Sample</th>
<th>P Population</th>
<th>I Intervention</th>
<th>C Comparison</th>
<th>O Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agarwal et al. (2020)</td>
<td>Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial</td>
<td>India</td>
<td>RCT</td>
<td>464</td>
<td>Moderate COVID-19 patients in 39 public and private hospitals in India</td>
<td>Convalescent Plasma 2x200 ml</td>
<td>Standard of care</td>
<td>Severe disease progression (PaO2/FiO2 &lt;100 mm Hg) and all-cause mortality at 28 days</td>
</tr>
<tr>
<td>Al-Qahtani et al. (2021)</td>
<td>Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease</td>
<td>Bahrain</td>
<td>RCT</td>
<td>40</td>
<td>COVID-19 patients requiring oxygen therapy and radiological evidence of pneumonia</td>
<td>Convalescent Plasma 200 ml</td>
<td>Standard of care</td>
<td>Need for ventilator, leukocyte count, actate dehydrogenase (LDH), C-reactive protein (CRP), Troponin, Ferritin, D-Dimer, procalcitonin, mortality at 28 days Need for mechanical ventilation, hospitalization &gt; 14 days, or hospital death</td>
</tr>
<tr>
<td>Balcells et al. (2021)</td>
<td>Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial</td>
<td>Santiago, Chili</td>
<td>RCT</td>
<td>57</td>
<td>Patients hospitalized within the first 7 days of COVID-19 symptoms, exhibiting risk factors for disease progression, without mechanical ventilation</td>
<td>Convalescent plasma 400 ml</td>
<td>Standard of care</td>
<td></td>
</tr>
<tr>
<td>Gharbharan et al. (2020)</td>
<td>Convalescent Plasma for COVID-19. A randomized clinical trial</td>
<td>Netherlands</td>
<td>RCT</td>
<td>86</td>
<td>Hospitalized COVID-19 patients in the Netherlands</td>
<td>Convalescent plasma minimum 1x300 ml with neutralizing antibody titer PRNT50 &gt; 1:80</td>
<td>Standard of care</td>
<td>Mortality on day 60, length of hospitalization, and increase in WHO 8-point disease severity scale on day 15</td>
</tr>
<tr>
<td>Li et al. (2020)</td>
<td>Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial</td>
<td>China</td>
<td>RCT</td>
<td>101</td>
<td>Severe/critical COVID-19 patients in 7 hospitals in India</td>
<td>Convalescent Plasma 1x200ml with S-RBD-specific Ig-G titer &gt;1:640</td>
<td>Standard of care</td>
<td>Clinical improvement within 28 days, mortality at 28 days, time to hospital discharge, and PCR results changing from positive at baseline</td>
</tr>
<tr>
<td>Study</td>
<td>Title</td>
<td>Study Location</td>
<td>Study Type</td>
<td>N</td>
<td>Patient Description</td>
<td>Comparator Description</td>
<td>Standard of care</td>
<td>Outcome Description</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------</td>
<td>----</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Libster et al. (2021)</td>
<td>Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults</td>
<td>Argentina</td>
<td>RCT</td>
<td>160</td>
<td>Mild COVID-19 patients, symptom onset &lt;72 hours old age/with comorbidities</td>
<td>Convalescent Plasma 1x250 ml, Ig-G spike titer requirement 1:1000</td>
<td>Standard of care</td>
<td>Development of severe respiratory disease, critical systemic illness, death</td>
</tr>
<tr>
<td>O’Donnell et al. (2021)</td>
<td>A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19</td>
<td>New York &amp; Brazil</td>
<td>RCT</td>
<td>223</td>
<td>Hospitalized adult patients with severe and critical COVID-19 at 5 locations in New York City (USA) and Rio de Janeiro (Brazil)</td>
<td>Convalescent Plasma 200-250 ml with a total anti-SARS-Cov-2 IgG antibody titer of at least 1:400</td>
<td>Standard of care</td>
<td>Clinical status at 28 days after randomization and death at 28 days</td>
</tr>
<tr>
<td>Simonovich et al. (2021)</td>
<td>A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia</td>
<td>Argentina</td>
<td>RCT</td>
<td>327</td>
<td>Severe COVID-19 patient in Argentina</td>
<td>Convalescent Plasma 1x500 ml, requirement for Ig-G spike titer 1:400</td>
<td>Standard of care</td>
<td>Death, invasive ventilation support, need for supplemental oxygen, and hospital discharge up to day 30</td>
</tr>
</tbody>
</table>
DISCUSSION

Since the publication of the first case series from China, several studies have reported an association between convalescent plasma and reduced mortality, hospitalization, and viral load in patients with COVID-19 (Joyner et al., 2020). A study conducted by Agarwal et al. (2020) revealed that there was no difference in 28-day mortality in moderate-grade COVID-19 patients treated with convalescent plasma. This is because the recipient has a higher neutralizing antibody titer than the convalescent plasma donor antibody titer. In addition, donors who are younger and have milder symptoms than recipients may drive this difference.

In the study (AlQahtani et al., 2021), patients who received early CP (less than 3 days from admission) had higher mean...
antibody levels in transfused plasma, than those who received CP after 3 days, although the difference was not significant. Significant. A previous study by Joyner et al., (2020), reported that patients who received early CP and with higher antibody titers performed better clinically. CP collected from donors showed variation in mean antibody levels, some extending to very low levels. The variability of antibody levels may affect plasma effectiveness and may decrease the effect of CP in this trial. The FDA has recommended using CPs with high antibody titers only, to prevent transfusions of CPs with low antibody levels which could be ineffective.

In this study (Balcells et al., 2021), the Anti Nab titer test using a sample with a neutralizing activity of at least 50% at a dilution of 1:160 was considered positive and was used to perform the titration curve and calculate the neutralization titer of the 50% inhibitory dose (ID50). The clearance rates of SARS-CoV-2 PCR on nasopharyngeal swabs also did not differ between study groups, suggesting that convalescent plasma administration in this study did not confer sufficient antiviral activity in patients with COVID-19 at this stage.

In the study (Li et al., 2020), a randomized controlled trial of 103 patients with severe and life-threatening COVID-19 in China. In that trial, a subgroup of 45 patients with severe disease showed no significant difference in the secondary outcome of 28-day mortality or time from randomization to discharge. Convalescent plasma treatment was associated with higher levels of negative SARS-CoV-2 virus PCR results from nasopharyngeal swabs at 24, 48, and 72 hours, suggesting that convalescent plasma treatment is associated with antiviral activity in patients with COVID-19.

In the study (Gharbharan et al., 2020), the ConCOVID trial from the Netherlands, which was terminated prematurely after 86 patients had enrolled, did not find any effect on death at 60 days, hospital stay, or disease severity at 15 days. The majority of patients in the ConCOVID study already had high viral neutralizing antibody titers on the day of study inclusion with titers comparable to 115 screen-recovered donors for convalescent plasma donation. When the study was designed, the timing of the development of neutralizing antibodies after SARS-CoV-2 infection was uncertain and the investigators considered it unlikely that most patients would have autologous neutralizing antibodies on the day of hospital admission. Almost all plasma donors had anti-SARS-CoV-2 antibodies but only 41% had a high neutralizing titer of at least 1:320. The solution might be to actively recruit recovered patients who have more severe COVID-19 disease as donors, as they have been shown to have higher antibody levels (Okba et al., 2020).

In the study of Joyner et al., (2021), reported that 7-day mortality and 30-day mortality were lower in those who received recovery plasma within three days of symptom onset. In patients with COVID-19 who were not receiving mechanical ventilation, plasma transfusions with high antibody levels were associated with a lower risk of death than plasma transfusions with low antibody levels. In addition, patients who received plasma within 3 days of receiving a Covid-19 diagnosis had a lower risk of death than those who received the transfusion later in the course of the disease.

In the study of O’Donnell et al., (2021), In this randomized, blinded, controlled phase 2 trial conducted in New York City and Rio de Janeiro, treatment with convalescent plasma compared with control plasma did not result in significant clinical improvement. at 28 days, based on an ordinal scale of clinical status, among adults
hospitalized with severe and critically ill COVID-19. However, mortality at 28 days was significantly lower among patients randomized to convalescent plasma. This effect on mortality was observed across analyzes adjusted for imbalances in baseline variables with prognostic relevance and in sensitivity analyzes performed to account for 28-day uncertain vital status in 8 patients. Although limited, available data suggest that the efficacy of treatment for convalescent plasma may depend on the duration of the disease and the severity and neutralizing titer of anti-SARS-CoV-2 antibodies in transfused plasma.

In one study (Libster et al., 2021), reported the use of convalescent plasma in older patients early in the course of Covid-19. Administration of convalescent plasma with high antibody titers against SARS-CoV-2 to infected patients within 72 hours of symptom onset reduced the risk of progression to severe respiratory disease by 48%. Researchers aim to stop disease progression early and at a mild stage. The researcher’s main end point was enrollment criteria in previous studies.

In a study (Simonovich et al., 2021), a recent clinical trial from Argentina reported that transfusion of high-titer convalescent plasma within 72 hours of symptom onset prevented progression of severe disease among elderly adults with mild COVID-19. High-titer convalescent plasma was associated with increased mortality among hospitalized patients who did not receive an invasive mechanical ventilator (IMV) at the time of transfusion. Although clinical status at 28 days did not differ significantly between the treatment groups, 28-day mortality was significantly lower among patients randomized to receive plasma recovery.

In several studies that did not find a clinical benefit of convalescent plasma therapy in these patients could be explained by several reasons. First, humoral immunity may not play a major role in the subset of patients who have initiated a highly pro-inflammatory response and in whom inflammation and coagulopathy may be more important than viral replication in disease progression (Polidoro et al., 2020). It is not known whether selection of plasma units with very high concentrations of NAbs or larger plasma volumes can successfully blunt this disordered inflammatory response. In addition, an early adaptive immune response may be required to promote more effective infection control. Indeed, distinct cellular and humoral responses are generated in mild versus severe cases of COVID-19, and it has been reported that specific cellular responses can be detected earlier in non-severe COVID-19 (Zhang et al., 2020). Second, the possible lack of efficacy may be related to plasma administration late in the course of the disease, in which an irregular immune response predominates and is independent of the blockade of viral cell entry achieved by immunoglobulins. Previous randomized trials of convalescent plasma for COVID-19 included patients who had a longer time gap between symptom onset and transfusion as well as more severe disease at enrollment (Li et al., 2020).

The results of the systematic study and meta-analysis are presented in the form of forest plots and funnel plots. The forest plot shows an overview of the information from each of the studies examined in the meta-analysis and estimates the overall results (Murti, 2018). Forest plots show visually the magnitude of variation (heterogeneity) between study results. A funnel plot is a diagram in a meta-analysis used to show possible publication bias. The funnel plot shows the relationship between the magnitude of the study effect and the sample size of the effect size of the various studies studied.
which can be measured in different ways (Murti, 2018).

The forest plot results from the Randomized Controlled Study design research article showed that convalescent plasma therapy reduced the risk of death in COVID-19 patients and was statistically significant (RR= 0.77; 95% CI= 0.64 to 0.93; p= 0.008). The heterogeneity of the research data shows I²= 3% so that the estimation is carried out using a fixed effect model approach.

This is in line with the results of a study conducted by Salazar et al, (2021) in Texas which stated that convalescent plasma transfusions in COVID-19 patients were performed immediately after hospitalization with high titer RBD IgG anti-spike protein present in convalescent plasma significantly reduce deaths.

In the study of Rasheed et al., (2020) also stated that convalescent plasma therapy is an effective therapy if a donor with high titer SARS-CoV2 antibodies is selected and if the recipient is in the early stages of critical illness, not more than three days in the RCU. Plasma from donors with high titers of SARS-CoV-2 IgG and donors with positive SRAS-CoV-2 IgM showed better therapeutic outcomes than other donors.

AUTHOR CONTRIBUTION
Fathiyyatu Assa’diy Firda is the lead researcher who chooses topics, searches for and collects research data. CSP Wekadinugawan and Bhisma Murti played a role in analyzing data and reviewing research documents.

CONFLICT OF INTEREST
There is no conflict of interest in this study.

FUNDING AND SPONSORSHIP
This study is self-funded.

ACKNOWLEDGMENT
We are very grateful to the provider databases, PubMed, Science Direct and Google scholar.

REFERENCES
16. DOI:10.1101/2020.07.01.201398857.


